ROYAL.BO · BSE
Royal Sense Limited
₹95.9
+2.02% (+₹1.9)
Prev. close
₹94
Volume
2,500
As of
24 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Royal Sense Limited
Royal Sense Limited engages in supplying various surgical accessories, tools, equipment, and other pharmaceutical products under the STERGIC brand name. It offers medical equipment, surgical instruments and consumables, laboratory equipment and reagents, medical consumables, diagnostics tools, sanitary products, pharmaceuticals, medicine, and cosmetics, as well as disposables. The company serves hospitals, laboratories, institutions, and clinics. Royal Sense Limited was founded in 2015 and is based in New Delhi, India.
Details
Sector
Healthcare
Industry
Medical Distribution
CEO
Mr. Rishabh Arora
Headquarters
New Delhi
Website
royalsense.inExchange
View on BSE ↗Key stats
Market cap
₹51.90 Cr
P/E ratio (TTM)
8.2
EPS (TTM)
₹11.83
Beta (1Y · daily vs NIFTY 50)
1.36
Shares float
16.67 L
Financial Performance
01 · Financials
FY22 growth needs FY21 filings, which the data source doesn't provide. Net income and EBITDA are omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures. Fiscal year-end moved from March to September between Mar 2024 and Sept 2024; the company's transition period bridged the two calendars, so no intermediate 12-month year exists — the "missing" column is a period that never was, not a data gap.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Sept 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| — | ₹0 | ₹17.80 Cr | ₹22.02 Cr | ₹61.73 Cr | ₹103.38 Cr | |
| EBITDA | — | ₹0 | ₹2.27 Cr | ₹3.22 Cr | ₹8.97 Cr | ₹11.07 Cr |
| — | ₹0 | ₹1.59 Cr | ₹2.38 Cr | ₹6.33 Cr | ₹7.15 Cr | |
| Diluted EPS | ₹0.45 | ₹0 | ₹3.24 | ₹4.85 | ₹11.83 | ₹12.46 |
This company moved its fiscal year-end; the transition period bridged the two calendars, so no intermediate 12-month year exists between the adjacent columns.
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Sept 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| ₹1.60 Cr | ₹7.37 Cr | ₹20.77 Cr | — | ₹35.56 Cr | — | |
| ₹31.80 L | ₹52.31 L | ₹1.60 Cr | — | ₹3.26 Cr | — | |
| Stockholders' equity | ₹65.43 L | ₹3.31 Cr | ₹18.22 Cr | — | ₹27.74 Cr | — |
This company moved its fiscal year-end; the transition period bridged the two calendars, so no intermediate 12-month year exists between the adjacent columns.
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Sept 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| — | ₹0 | ₹-3.87 Cr | ₹-4.57 Cr | ₹1.21 Cr | — | |
| Investing cash flow | — | ₹0 | ₹-51.64 L | ₹-1.06 Cr | ₹-1.56 Cr | — |
| — | ₹0 | ₹13.13 Cr | ₹-4.87 L | ₹2.86 Cr | — | |
| Capital expenditure | — | — | ₹-3.35 L | ₹-1.61 L | ₹-1.62 Cr | — |
| End cash position | — | ₹0 | ₹8.74 Cr | ₹3.07 Cr | ₹11.25 Cr | — |
This company moved its fiscal year-end; the transition period bridged the two calendars, so no intermediate 12-month year exists between the adjacent columns.
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.47 L Cr | ₹1,849.9 | 37.0 | 5.35 | 13.7% | 0.06 | +11.9% | +13.7% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,602 | 87.2 | 15.24 | 15.3% | 0.00 | +12.3% | +60.5% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.30 L Cr | ₹8,888.5 | 61.0 | 13.75 | 20.5% | 0.90 | +15.7% | +16.3% |
| Lenskart Solutions Limited | ₹1.19 L Cr | ₹676 | 180.7 | 13.61 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,399 | 33.2 | 3.24 | 11.3% | 0.02 | +2.1% | -9.0% |
| Laurus Labs Limited | ₹1.10 L Cr | ₹2,026.2 | 100.9 | 20.84 | 16.8% | 0.48 | +22.0% | +122.7% |
| Max Healthcare Institute Limited | ₹1.03 L Cr | ₹1,046 | 71.1 | 9.60 | 13.4% | 0.32 | +19.0% | -7.7% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,200.4 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.5% |
| Royal Sense Limited | ₹51.90 Cr | ₹94 | 8.2 | 1.87 | 22.8% | 0.12 | +180.3% | -64.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
ROYAL SENSE LIMITED: Promoter Encumbers 18.69% Shares for Financial Assistance
A promoter of Royal Sense Ltd., Rishabh Arora, encumbered 1,000,000 shares, representing 18.69% of the total share capital. This action was taken to secure financial assistance. The post-event holding of encumbered shares remains at 18.69%.